Egetis Therapeutics (EGTX) Leerink Global Healthcare Conference 2026 summary

Strategic focus and recent progress

• Focused on late-stage development and commercialization of treatments for rare diseases, with Emcitate as the lead candidate for MCT8 deficiency.

• Emcitate received EU approval as the first and only therapy for MCT8 deficiency and was granted FDA breakthrough designation based on mortality data.

• Rolling NDA submission for Emcitate was initiated in December and completed in January; FDA acceptance for filing expected by March 29.

• FDA supported NDA submission with current data, granted rolling submission, and allowed early closure of the pivotal ReTRIACt study.

Clinical data and regulatory pathway

• Mortality risk in treated patients is over three times lower than in untreated patients, supported by multiple clinical studies.

• Statistical analysis plan for ReTRIACt was updated to include a new primary endpoint, showing a 59% increase in T3 rate of change for placebo patients (p=0.034).

• NDA submission includes data from six sources, including long-term and survival studies, with over 600 patients in mortality data.

• Clear link established between elevated T3 and mortality; treatment reduces mortality, which is the ultimate clinical outcome.

Commercialization and market insights

• EU launch in Germany led to exponential increase in diagnosed patients, highlighting low disease awareness and underdiagnosis.

• U.S. diagnosed patient pool grew from 28 to 145 since 2021, with estimated true prevalence of 1,000–1,500 patients.

• Pre-launch U.S. activities include expanding the team to 25 by launch, focusing on disease awareness and physician engagement.

• Manufacturing is streamlined with API from Switzerland, drug product from France, and U.S. distribution via 3PL and specialty pharma.